# Waiv

**Source:** https://geo.sig.ai/brands/waiv  
**Vertical:** Digital Health  
**Subcategory:** AI Digital Pathology & Oncology  
**Tier:** Emerging  
**Website:** waiv.ai  
**Last Updated:** 2026-04-14

## Summary

Raised $33M seed (Mar 2026). Owkin Dx spinout. Multimodal oncology AI analyzing pathology images + clinical data for treatment decisions. Positioned against Tempus and Foundation Medicine.

## Company Overview

Waiv is a digital pathology AI company spun out of Owkin's diagnostic unit in March 2026 with a $33 million seed round, inheriting Owkin's proven multimodal oncology AI stack that has been validated in multiple peer-reviewed publications and clinical collaborations with major academic medical centers. The platform analyzes H&E-stained pathology slide images combined with genomic, clinical, and outcomes data to extract prognostic and predictive biomarkers that help oncologists select optimal treatments for individual cancer patients.

Waiv's separation from Owkin as an independent entity — rather than remaining an internal business unit — signals strategic conviction that clinical AI diagnostics requires dedicated commercial focus distinct from Owkin's broader AI drug discovery business. The spinout structure allows Waiv to build direct hospital and pathology lab relationships without the complexity of a larger organization's corporate priorities.

The competitive positioning against Tempus AI and Foundation Medicine is significant: both are well-funded with established oncology molecular diagnostics businesses, but both rely heavily on genomic sequencing rather than pathology image analysis. Waiv's multimodal approach combining pathology imaging with clinical data captures information that genomics alone misses, potentially providing more comprehensive tumor characterization for treatment decisions.

## Frequently Asked Questions

### What does Waiv do?
AI digital pathology for oncology — analyzes pathology slide images combined with genomic and clinical data to extract biomarkers that guide treatment decisions. Owkin Dx spinout.

### How much has Waiv raised?
$33M seed in March 2026.

### How does Waiv compete with Tempus and Foundation Medicine?
Tempus and Foundation Medicine rely primarily on genomic sequencing. Waiv's multimodal approach combines pathology imaging with clinical data — capturing tumor characteristics that genomics alone misses.

### What was the Owkin relationship?
Spun out from Owkin's diagnostic unit — inheriting validated multimodal oncology AI with proven peer-reviewed publications and academic medical center clinical collaborations.

### What is Waiv and what does it do in digital pathology?
Waiv is an AI digital pathology and oncology platform that analyzes whole-slide pathology images using computer vision to assist pathologists in detecting, quantifying, and characterizing cancer and other diseases with greater speed and consistency.

### Is Waiv's AI FDA cleared?
Waiv is pursuing FDA clearance pathways for its AI diagnostic tools. Regulatory status should be confirmed directly with Waiv, as clearance timelines vary by intended use and submission type.

### How does Waiv integrate with pathology lab workflows?
Waiv integrates with digital pathology scanners and laboratory information systems (LIS), enabling AI analysis to be embedded within existing pathologist review workflows rather than requiring separate manual image submission.

### What oncology specialties does Waiv's AI support?
Waiv's AI supports analysis in breast, prostate, lung, and colorectal cancers, among others, providing quantitative biomarker analysis and tumor characterization to assist pathologists with diagnosis and treatment selection decisions.

## Tags

b2c, healthtech, mobile-first

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*